HDAC3: a new target for atherosclerosis therapy

Zihan Xia; He Zhang; Ziqiong Zhang; Xingyi Li; Yining Wang; Weirong Wang

doi:10.20039/j.cnki.1007-3949.2024.07.010

HDAC3: a new target for atherosclerosis therapy

Zihan Xia
, He Zhang
, Ziqiong Zhang
, Xingyi Li
, Yining Wang
, Weirong Wang

Health Science Center

Xi'an Jiaotong University

Research output: Contribution to journal › Article › peer-review

Abstract

Histone deacetylase 3 (HDAC3) is an epigenetic modification enzyme, which participates in the occurrence and development of atherosclerosis (As). It is significant to search for effective HDAC3 inhibitors for the treatment of atherosclerosis. This article reviews the relationship between HDAC3 and atherosclerosis, the latest research progress of HDAC3 inhibitors, and the therapeutic effects of some traditional Chinese medicine on cardiovascular diseases by inhibiting HDAC3. It aims to provide new ideas for developing anti-atherosclerotic drugs targeting HDAC3.

Original language	English
Pages (from-to)	621-626
Number of pages	6
Journal	Zhongguo Dongmai Yinghua Zazhi
Volume	32
Issue number	7
DOIs	https://doi.org/10.20039/j.cnki.1007-3949.2024.07.010
State	Published - 2024

Keywords

atherosclerosis
histone deacetylase 3
inhibitors
traditional Chinese medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.20039/j.cnki.1007-3949.2024.07.010

Cite this

@article{bde79c8cb137491ea31bcd5afa329cf8,

title = "HDAC3: a new target for atherosclerosis therapy",

abstract = "Histone deacetylase 3 (HDAC3) is an epigenetic modification enzyme, which participates in the occurrence and development of atherosclerosis (As). It is significant to search for effective HDAC3 inhibitors for the treatment of atherosclerosis. This article reviews the relationship between HDAC3 and atherosclerosis, the latest research progress of HDAC3 inhibitors, and the therapeutic effects of some traditional Chinese medicine on cardiovascular diseases by inhibiting HDAC3. It aims to provide new ideas for developing anti-atherosclerotic drugs targeting HDAC3.",

keywords = "atherosclerosis, histone deacetylase 3, inhibitors, traditional Chinese medicine",

author = "Zihan Xia and He Zhang and Ziqiong Zhang and Xingyi Li and Yining Wang and Weirong Wang",

year = "2024",

doi = "10.20039/j.cnki.1007-3949.2024.07.010",

language = "英语",

volume = "32",

pages = "621--626",

journal = "Zhongguo Dongmai Yinghua Zazhi",

issn = "1007-3949",

publisher = "Editorial Office of Chinese Journal of Arteriosclerosis ",

number = "7",

}

TY - JOUR

T1 - HDAC3

T2 - a new target for atherosclerosis therapy

AU - Xia, Zihan

AU - Zhang, He

AU - Zhang, Ziqiong

AU - Li, Xingyi

AU - Wang, Yining

AU - Wang, Weirong

PY - 2024

Y1 - 2024

N2 - Histone deacetylase 3 (HDAC3) is an epigenetic modification enzyme, which participates in the occurrence and development of atherosclerosis (As). It is significant to search for effective HDAC3 inhibitors for the treatment of atherosclerosis. This article reviews the relationship between HDAC3 and atherosclerosis, the latest research progress of HDAC3 inhibitors, and the therapeutic effects of some traditional Chinese medicine on cardiovascular diseases by inhibiting HDAC3. It aims to provide new ideas for developing anti-atherosclerotic drugs targeting HDAC3.

AB - Histone deacetylase 3 (HDAC3) is an epigenetic modification enzyme, which participates in the occurrence and development of atherosclerosis (As). It is significant to search for effective HDAC3 inhibitors for the treatment of atherosclerosis. This article reviews the relationship between HDAC3 and atherosclerosis, the latest research progress of HDAC3 inhibitors, and the therapeutic effects of some traditional Chinese medicine on cardiovascular diseases by inhibiting HDAC3. It aims to provide new ideas for developing anti-atherosclerotic drugs targeting HDAC3.

KW - atherosclerosis

KW - histone deacetylase 3

KW - inhibitors

KW - traditional Chinese medicine

UR - https://www.scopus.com/pages/publications/85209348211

U2 - 10.20039/j.cnki.1007-3949.2024.07.010

DO - 10.20039/j.cnki.1007-3949.2024.07.010

M3 - 文章

AN - SCOPUS:85209348211

SN - 1007-3949

VL - 32

SP - 621

EP - 626

JO - Zhongguo Dongmai Yinghua Zazhi

JF - Zhongguo Dongmai Yinghua Zazhi

IS - 7

ER -

HDAC3: a new target for atherosclerosis therapy

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this